

Finding solutions to challenging and complex Cochrane reviews:

the National Institute for Health Research
Complex Reviews Support Unit (NIHR CRSU)

Outline

- NIHR CRSU
- Supporting complex reviews
- A Cochrane network meta-analysis: early mobilisation after stroke
- An app for network meta-analysis - MetaInsight
- Network meta-analysis of complex interventions - Component Analysis
- Further complex reviews issues

NIHR CRSU - Complex Reviews Support Unit

About us

The Team

Apply for CRSU Support

Materials and Guidance

Courses and Conferences

FAQs

Contact us




About us

NIHR CRSU: Supporting Successful Delivery of Complex Reviews



The Team



Apply for CRSU Support

Submit an application for support to CRSU



Materials and Guidance

Materials and links to current guidance

Our Expertise

- Network meta-analysis
- Diagnostic test accuracy reviews
- Individual participant data meta-analysis
- Narrative synthesis
- Realist synthesis
- Economic evidence
- Use of routine data
- Non-randomised studies
- Prognostic reviews
- Prevalence reviews

Supporting Cochrane Reviews – Advice and Training

- Reviewers
- Review Groups
- Incentive Awards
- Programme Grants
- Editorial Teams
- Refining review questions
- Consideration of types of data and data structure
- Methodological approaches
- Applications, protocols and reporting

Complex Reviews in Hepato-Biliary Disorders

Priority topics in the diagnosis and management of liver, gallbladder, and biliary tract disorders

Kurinchi Gurusamy and colleagues

- Series of reviews of treatment for different indications
- Complex interventions – life-style modification
- Multiple treatment comparisons (network meta-analysis)

Complex Reviews in Oral Health

Detection and diagnosis of dental caries

Richard Macey and colleagues

- Variation in thresholds
- Imperfect reference standards
- Multiple examiners
- Multiple measurements per person

Complex Reviews in COPD

Priority topics:

- Prognostic factors at EoL
- Use of weather forecasting/pollution monitoring
- Care pathways for multi-morbidity
- Prophylactic antibiotics
- Complex questions
- Utility of the review
- Feasibility of quantitative synthesis
- Multiple treatment comparisons (network meta-analysis)

Rebecca Normansell and colleagues



NIHR CRSU - Complex Reviews Support Unit

About us

The Team

Apply for CRSU Support

Materials and Guidance

Courses and Conferences

FAQs

Contact us >

Contact us

Moira Sim

Project Manager

NIHR Complex Reviews Support Unit (CRSU)

1 Lilybank Gardens

University of Glasgow

Glasgow

G12 8RZ

Telephone: 0141 330 6826

E-mail: moira.sim@glasgow.ac.uk

Website: www.nihrcrsu.org

Twitter: @NIHRCRSU



University
of Glasgow



UNIVERSITY OF
LEICESTER

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



NHS
National Institute for
Health Research

Early mobilisation after stroke: Meta-analysis approaches

Peter Langhorne,
Professor of stroke care,
Glasgow University



Limited evidence for individual components of stroke unit care




Figure 3: Key components of stroke-unit care

Limited evidence for individual components of stroke unit care




Figure 3: Key components of stroke-unit care

2104 participants recruited
56 centres (5 countries)
2006 - 2014
Complete follow up 2083 (99%)



Europe

Asia

Australasia



15TL1709_Bernhardt

Articles

ZN

This version saved: 12:43 13-Apr-15

THELANCET-D-15-01709
S0140-6736(15)60690-0
Embargo: April 17, 2015—00:01 (BST)
GOLD OA CC BY-NC-ND

Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial



The AVERT Trial Collaboration group*



Summary

Background Early mobilisation after stroke is thought to contribute to the effects of stroke-unit care; however, the intervention is poorly defined and not underpinned by strong evidence. We aimed to compare the effectiveness of frequent, higher dose, very early mobilisation with usual care after stroke.

Published Online
April 12 2015
[http://dx.doi.org/10.1016/S0140-6736\(15\)60690-0](http://dx.doi.org/10.1016/S0140-6736(15)60690-0)
See Online/Comment
<http://dx.doi.org/10.1016/PI>

Methods We did this parallel-group, single-blind, randomised controlled trial at 56 acute stroke units in five countries. Patients (aged ≥ 18 years) with ischaemic or haemorrhagic stroke, first or recurrent, who met physiological criteria were randomly assigned (1:1), via a web-based computer generated block randomisation procedure (block size of six), to receive usual stroke-unit care alone or very early mobilisation in addition to usual care. Randomisation was stratified by study site and stroke severity. Patients, outcome assessors, and investigators involved in trial and data management were masked to treatment allocation. The primary outcome was a favourable outcome 3 months after stroke, defined as a modified Rankin Scale score of 0–2. We did analysis on an intention-to-treat basis. The trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12606000185561.


*Members listed in the appendix
Correspondence to:
Prof Julie Bernhardt, The Florey
Institute of Neuroscience and
Mental Health, Austin Campus,
Heidelberg, VIC 3084, Australia
julie.bernhardt@florey.edu.au
See Online for appendix

Findings Between July 18, 2006, and Oct 16, 2014, we randomly assigned 2104 patients to receive either very early mobilisation (n=1054) or usual care (n=1050); 2083 (99%) patients were included in the 3 month follow-up assessment. 965 (92%) patients were mobilised within 24 h in the very early mobilisation group compared with 623 (59%) patients in the usual care group. Fewer patients in the very early mobilisation group had a favourable outcome than those in the usual care group (n=480 [46%] vs n=525 [50%]; adjusted odds ratio [OR] 0.73, 95% CI 0.59–0.90; p=0.004). 88 (8%) patients died in the very early mobilisation group compared with 72 (7%) patients in the usual care group (OR 1.34, 95% CI 0.93–1.93, p=0.113). 201 (19%) patients in the very early mobilisation group and 208 (20%) of those in the usual care group had a non-fatal serious adverse event, with no reduction in immobility-related complications with very early mobilisation.

Interpretation First mobilisation took place within 24 h for most patients in this trial. The higher dose, very early mobilisation protocol was associated with a reduction in the odds of a favourable outcome at 3 months. Early mobilisation after stroke is recommended in many clinical practice guidelines worldwide, and our findings should affect clinical practice by refining present guidelines; however, clinical recommendations should be informed by future analyses of dose–response associations.

Funding National Health and Medical Research Council, Singapore Health, Chest Heart and Stroke Scotland, Northern Ireland Chest Heart and Stroke, UK Stroke Association, National Institute of Health Research.

Copyright © Bernhardt et al. Open Access article distributed under the terms of CC BY-NC-ND.



+854 participants recruited

+20 centres (7 countries)

2008 - 2016

Complete follow up 2548/2618 (97%)



Primary outcome:
Dead or disabled (mRS 3-6) at 3 months

Secondary outcomes:
Death by 3 months

Exploratory analyses:
Time to first mobilisation (TTFM)



What is Very Early Mobilisation (VEM)?



- Out of bed mobilisation within 48 hours of stroke
- Aimed to reduce time to first mobilisation (TTFM)
 - with or without an increase in the amount or frequency of mobilisation activities
- Compared with usual care
 - time to first mobilisation commenced later
- Interventions provided by a physiotherapist ± nurse team
- Protocol/training provided to staff



Mobilisation trials (Time to first mobilisation)

Across all the trials in the Cochrane review:

Group	Median (range) TTFM
Very early mobilisation (VEM)	18 (13 - 43) hours
Usual care (UC)	33 (23 - 72) hours
Within trial difference (UC – VEM)	13 (4 - 46) hours

Cochrane review (update in progress)

Trials of very early mobilisation


Trial	Aim	Early mobilisation TTFM (hours)	Usual Care TTFM (hours)	Frequency of mobilisation events per day	Average amount of mobilisation activity
AKEMIS 2012	Earlier	13.1 (8.5-25.6)	33.3 (26.0-39.0)	Not stated	Not stated
AVERT II 2008	Earlier & more	18.1 (12.8-21.5)	30.8 (23.0-39.9)	2 vs 0	167 vs 69 mins mobilisation activity
AVERT III 2015	Earlier & more	18.5 (12.8-22.3)	22.4 (16.5-29.3)	6.5 vs 3	31 vs 10 mins per day of mobilisation activity
Glasgow 2010	Earlier & more	27.3 (26.0-29.0)	32.0 (22.5-47.3)	Not stated	More EM patients (P=0.02) achieved standing or walking
Mangalore 2015a	Earlier & more	18 (16.6-19.8)	30.5 (29.0-35.0)	Not stated	Extra 5-30 mins per day of out of bed activity
Mangalore 2015b	Earlier & more	Same as 2015a	Same as 2015a	Same as 2015a	Same as 2015a
Porto Allegre 2015	Earlier & more	43	72	0.54 vs 0.03	Extra 30 mins per day of out of bed activity
Rome 2016	Earlier	<24	96	Not stated	60 mins per day for first 4 days
SEVEL 2016	Earlier	25.9 (22.5-29.3)	71.5 (68.1-74.9)	Not stated	83.7 vs 56.6 mins per day

Trials of very early mobilisation

Trial	Aim	Early mobilisation TTFM (hours)	Usual Care TTFM (hours)	Frequency of mobilisation events per day	Average amount of mobilisation activity
AKEMIS 2012	Earlier	13.1 (8.5-25.6)	33.3 (26.0-39.0)	Not stated	Not stated
AVERT II 2008	Earlier & more	18.1 (12.8-21.5)	30.8 (23.0-39.9)	2 vs 0	167 vs 69 mins mobilisation activity
AVERT III 2015	Earlier & more	18.5 (12.8-22.3)	22.4 (16.5-29.3)	6.5 vs 3	31 vs 10 mins per day of mobilisation activity
Glasgow 2010	Earlier & more	27.3 (26.0-29.0)	32.0 (22.5-47.3)	Not stated	More EM patients (P=0.02) achieved standing or walking
Mangalore 2015a	Earlier & more	18 (16.6-19.8)	30.5 (29.0-35.0)	Not stated	Extra 5-30 mins per day of out of bed activity
Mangalore 2015b	Earlier & more	Same as 2015a	Same as 2015a	Same as 2015a	Same as 2015a
Porto Allegre 2015	Earlier & more	43	72	0.54 vs 0.03	Extra 30 mins per day of out of bed activity
Rome 2016	Earlier	<24	96	Not stated	60 mins per day for first 4 days
SEVEL 2016	Earlier	25.9 (22.5-29.3)	71.5 (68.1-74.9)	Not stated	83.7 vs 56.6 mins per day

Early Mobilisation trials – Network meta-analysis



TTFM (time to first mobilisation) groups



Cochrane review (update in progress)

Early Mobilisation trials – Network meta-analysis


TTFM (time to first mobilisation) groups



Cochrane review (update in progress)

Early Mobilisation trials – Network meta-analysis

TTFM (time to first mobilisation) groups




Cochrane review (update in progress)

Early Mobilisation trials – Network meta-analysis

TTFM (time to first mobilisation) groups


TTFM group Odds ratio (95% CI) of a poor outcome




→
Poorer outcome (dead or disabled at 3 months)

Early Mobilisation trials – Network meta-analysis

TTFM (time to first mobilisation) groups



Early mobilisation after stroke



1. Very early (<24 hours) higher dose out of bed activity protocol reduced the odds of favourable outcome
2. Exploratory analysis suggests no TTFM was better than 24 hours
3. Guideline advice seems appropriate at present:
“Patients with difficulty moving early after stroke who are medically stable should be offered frequent, short daily mobilisations typically beginning between 24 and 48 hours of stroke onset”
4. Work in progress!



Thank you for
your attention

MetaInsight: an interactive web-based tool for analyzing, interrogating and visualizing network meta-analyses

Rhiannon K Owen


 **@RhiannonKOwen**

Acknowledgements: Naomi Bradbury,
Nicola Cooper, Alex Sutton

MetaInsight Home Continuous Data Continuous Meta-analysis

MetaInsight (continuous)

[For binary outcomes please click here.](#)



Rhiannon K Owen, Naomi Bradbury, Nicola Cooper, Alex Sutton



MetaInsight demonstration

If you would like to follow the demo on your own device please scan the QR code or go to:

<https://crsu.shinyapps.io/metainsightc/>



NIHR CRSU

Complex Reviews Support Unit

Component Network

Meta-Analysis

The Complex Reviews Support Unit (CRSU) is funded by the National Institute for Health Research (project number 14/178/29)

Department of Health Disclaimer:

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NIHR, NHS or the Department of Health

Background

- May 2016 - Meta-analysis published in the Cochrane Database of Systematic Reviews identifying better postoperative outcomes (e.g. reduced length of stay in hospital, lower pain, reducing negative emotion) for patients who received any psychological preparation (strategies designed to influence thoughts, feelings or actions) compared to usual care



**Cochrane
Library**

Cochrane Database of Systematic Reviews

**Psychological preparation and postoperative outcomes for
adults undergoing surgery under general anaesthesia
(Review)**

Powell R, Scott NW, Manyande A, Bruce J, Vögele C, Byrne-Davis LMT, Unsworth M, Osmer C,
Johnston M


What is Psychological Preparation?

- Can be considered as the intervention received by patients prior to surgery to help prepare them for surgery and minimise length of stay, pain and negative affect
- Psychological preparation can consist of multiple components:
 - Procedural information (What, when and how events will occur)
 - Sensory information (What it will feel/smell like)
 - Behavioural instruction (Teaching patients actions to perform to enhance the experience)
 - Cognitive intervention (To change how an individual thinks)
 - Relaxation (including hypnosis)
 - Emotion-focused techniques (To help an individual manage their feelings)

What did they do in the Cochrane review?


Wanted to answer the question:

“What is the effect of psychological preparation on postoperative outcomes in adults undergoing elective surgery under general anaesthetic?”



Assumptions in the Cochrane review?

- All intervention arms were assumed to be equally effective irrespective of which treatment components were administered



Assumptions:

- The effect of each component of intervention is the same
- The effect of a single component is the same as a combination of components

Additional Questions for NMA

- Which individual components of psychological preparation before surgery are associated with better outcomes?
- Are components more effective when delivered on their own or in combination?
- Are component effects associated with control group risk? (i.e. Does length of stay in the control group affect length of stay in the intervention group?)
- Are component effects associated with type of surgery?

Modelling Component Effects (1)

Let d represent the treatment effect, b the baseline treatment and k the intervention

Component effects can be accounted for by varying the assumption for

d_{bk}

Pairwise Meta-Analysis (any intervention vs no intervention)

$$d_{bk} = d$$

Network Meta-Analysis (each unique combination of interventions treated as a separate 'treatment')

$$d_{bk} = d_{bk}$$

Modelling Component Effects (2)

Component NMA models

- **Additive effects:** separates out the component effects

$$d_{bk} = d_P + d_S + d_B + d_C + d_R + d_E$$

where d_P is an indicator variable taking the value 1 if P is a component of treatment k and 0 otherwise


- **Pairwise interactions between components:** allows the effect of a combination to be greater/less than the sum of its individual components

$$d_{bk} = d_P + d_S + d_B + d_C + d_R + d_E + d_{PS} + d_{PB} + \dots + d_{RE}$$

Modelling Component Effects (3)

- Study level covariates:
 - Control group risk
 - Type of surgery
- Software
 - All models fitted in WinBUGS
- Comparison of models
 - using the Deviance Information Criteria (DIC) but clinical expertise also sought to ensure appropriate model selected

Network Diagram for Length of Stay




P = procedural information, S = sensory information, B = behavioural instruction, C = cognitive intervention, R = relaxation techniques, E = emotion-focused intervention

Length of Stay

- 35 trials including four three-arm trials and two four-arm trials
- 18 interventions
- Continuous outcome – number of days in hospital
- All trials had a ‘no intervention’ control arm
- Cochrane review identified any intervention reduces length of stay by 0.52 days (95% CrI: -0.82, -0.22)

Length of Stay Forest Plot




Length of Stay – Additive Effects

Intervention	Mean (95% Credible Interval)
Control group risk (centered on mean of 9 days)	-0.098 (-0.157, -0.043)
Procedural information (P)	-0.308 (-1.022, 0.360)
Sensory information (S)	-0.313 (-1.004, 0.439)
Behavioural instruction (B)	-0.561 (-1.047, -0.111)
Cognitive intervention (C)	-0.444 (-1.106, 0.214)
Relaxation techniques (R)	-0.368 (-1.154, 0.412)
Emotion-focused techniques (E)	1.296 (-0.028, 2.700)


For every one day increase in control group length of stay, the length of stay in the intervention arm is reduced by 0.1 days

Effect of type of surgery on length of stay



Most effective component dependent on type of surgery

Simultaneous assessment across outcomes



Summary

- For all three outcomes the additive effects model was most appropriate
 - No important pairwise interactions between components were identified for any outcome
- Reduction in length of stay and negative emotion were associated with control group risk
- Procedural information, sensory information and behavioural instruction may reduce length of stay but this depends on type of surgery
- Relaxation effective at reducing pain
- No single component identified as most effective across all three outcomes

Limitations

- We only assessed pairwise interactions and the model may have been underpowered to identify pairwise interactions as there were few studies evaluating each component
 - There may be interactions between three or more components but too few studies to evaluate
- We assumed consistency between the direct and the indirect evidence but were unable to test this assumption
- Between-study heterogeneity only partly explained by inclusion of control group risk as a covariate
 - Is an additive scale inappropriate?
 - Could a ratio scale be better?

Conclusions

- Component network meta-analysis added value to an existing meta-analysis
 - Allowed us to answer more clinically relevant questions regarding effectiveness of individual components
- Component network meta-analysis could be more widely used in systematic reviews involving complex interventions
- This approach could be utilised when considering cost-effectiveness - more intensive interventions may be justified on cost-effectiveness grounds for certain types of surgery

Ongoing Projects in Component NMA

- Cochrane Tobacco Addiction
 - Behavioural interventions for smoking cessation
- Cochrane Dementia & Cognitive Improvement
 - Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients

References

Freeman SC, Scott NW, Powell R, Johnston M, Sutton AJ, Cooper NJ. Component network meta-analysis identifies the most effective components of psychological preparation for adults undergoing surgery under general anesthesia. *Journal of Clinical Epidemiology* 2018 <https://doi.org/10.1016/j.jclinepi.2018.02.012>

Powell R, Scott NW, Manyande A, et al. *Cochrane Database of Systematic Reviews* 26 MAY 2016 DOI: 10.1002/14651858.CD008646.pub2
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008646.pub2/full#CD008646>

Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. *Am J Epidemiol* 2009;169 (9);1158-1165

NIHR CRSU

Complex Reviews Support Unit

Further Topics

The Complex Reviews Support Unit (CRSU) is funded by the National Institute for Health Research (project number 14/178/29)


Department of Health Disclaimer:

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NIHR, NHS or the Department of Health


OUTLINE

- ✓ Network meta-analysis
 - Diagnostic Test Accuracy Reviews
 - DTA-MA App https://crsu.shinyapps.io/dta_ma/
 - Individual patient data
 - Prognostic Reviews
 - Sequential analysis
 - Using evidence synthesis to help inform the next study
 - Non-statistical synthesis of qualitative data
 - How can the CRSU help your group

Diagnostic Test Accuracy Meta-analysis



Diagnostic Test Accuracy Meta-Analysis



Tuesday 18th September 11:00 –
11:10 Carrick 3, OS43
**'An interactive web application to aid
diagnostic test accuracy meta-
analysis'**

https://crsu.shinyapps.io/dta_ma/

Suzanne Freeman, Clareece Kerby, Nicola Cooper, Alex Sutton

For feedback/questions about this app please contact suzanne.freeman@leicester.ac.uk

App powered by Rshiny with statistical analyses performed using the package lme4:

<https://CRAN.R-project.org/package=lme4>

Individual Patient Data (IPD)


- Desirable
- Can greatly improve power and reliability of patient level covariate (e.g. subgroup) analyses
- IPD models for pairwise meta-analysis and NMA possible
- IPD diagnostic test models evolving
- Often not possible to obtain IPD from all relevant studies
 - Methods to use IPD where available and summary data otherwise exist

Prognostic Reviews

- First Cochrane pilots / exemplar reviews underway
- Under developed area
- Seek guidance from Cochrane Prognostic Review Methods Group in the first instance
- CRSU has some, but not extensive, experience

Trial Sequential Analysis (TSA)

- TSA used to adjust meta-analysis for multiple looks at the data when a M-A is updated
 - Similar to interim analysis in a single clinical trial
 - Crudely, the effect will be to make p-values less “significant”



Using evidence synthesis to help inform the next study

- Related to TSA is the issue of how a meta-analysis should inform the design of future studies
 - Including comparators & sample size
- Would you be comfortable with a £1 million trial going ahead that had 0 chance of changing the conclusion of an existing meta-analysis?
 - When there is some heterogeneity this is very possible(!)
- Should Cochrane reviews place more emphasis here and play an active role in Evidence Based Research?
 - “Inform the future as well as summarise the past”

Narrative synthesis of qualitative data

- Textually describing the overall effect noting variations in study characteristics, implementation, etc.
- Synthesis involved bringing data together at some level – more than simply summarising one study at a time
- Used when high level of heterogeneity contra-indicate meta-analysis
 - Not just when statistical heterogeneity – other sources include study design, conceptual (intervention, outcome, context, population)
- Identifies patterns and explanations for variation in effects
 - E.g. what works for who, in what circumstances
- Workshops on this over the last couple of days by Hilary Thomson and others.

How can CRSU help your group

Archie

Organizer Resources Search

File View Tools Favourites Help

Quick Search:

Terry J Quinn 11:12
Dementia and Cognitive Improvement Group

Resources

Active | 182

Title	Contact Person	Rev No	Write Ph
11C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) (DTA 17)	Zhang, Shuo	DTA 17	Authoring
18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)	Martinez, Gabriel		Authoring
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)	Martinez, Gabriel		Authoring
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)	Martinez, Gabriel		Authoring
18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) (DTA 23)	Sachpekidis, Christ	DTA 23	Authoring
AD-8 for diagnosis of dementia across a variety of healthcare settings	Hudson, Sheila A	133	Authoring
Acetyl-L-carnitine for dementia (133)	Peng, Weina		Authoring
Acupuncture for vascular dementia	Quinn, Terry J		Authoring
Aerobic exercise to improve cognitive function in older people without known cognitive impairment (128)	Young, Jeremy	128	Authoring
Almitrine-Raubasine combination for dementia	Yang, Weimin		Authoring
Alpha lipoic acid for dementia (139)	Klugman, Anthony	139	Authoring
Antidepressants for agitation and psychosis in dementia	Seitz, Dallas P		Authoring
Antidepressants for treating depression in dementia	Dudas, Robert	24	Authoring
Antihypertensive withdrawal for the prevention of cognitive decline	Quinn, Terry J		Authoring
Antipsychotics for treatment of delirium in hospitalised non-ICU patients	Burry, Lisa		Authoring
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia	Kwan, Joseph SK		Authoring
Aromatherapy for dementia (56)	Gray, Amy	56	Authoring
Art therapy for people with dementia	Deshmukh, Sunita		Editorial
Aspirin and anti-inflammatory drugs for the prevention of dementia	Jordan, Fionnuala		Editorial
Aspirin for vascular dementia	Rands, Gianetta	33	Authoring
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease (119)	Jaturapatporn, Dari	119	Authoring
Assistive technology for memory support in dementia	Van der Roest, He		Authoring
Atypical antipsychotics for agitation and psychosis in dementia	Köppe, Sascha		Editorial
Benzodiazepines for delirium (5)	Shang, Hong Cai	5	Editorial
Benzodiazepines for treatment of delirium in non-ICU settings	Shang, Hong Cai		Authoring
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) (DTA 19)	Krishnan, Sarada	115	Editorial
Cannabinoids for the treatment of Alzheimer's dementia and vascular dementia (115)	Puljak, Livia		Authoring
Cannabinoids for the treatment of dementia	Ooi, Cheow Peng	117	Authoring
Carbohydrates for improving the cognitive performance of independent-living older adults with normal cognition or mild cognitive impairment (117)	Reilly, Siobhan		Authoring
Case management approaches to home support for people with dementia	He, Li		Editorial
Cerebrolysin for vascular dementia	Birks, Jacqueline S		Authoring
Cholinesterase inhibitors for Alzheimer's disease	Overshott, Ross	102	Editorial
Cholinesterase inhibitors for Parkinson's disease dementia	Wild, Rebecca		Authoring
Cholinesterase inhibitors for delirium (102)	Martinez, Gabriel		Authoring
Cholinesterase inhibitors for dementia with Lewy bodies	Russ, Tom C		Authoring
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease	Maidment, Ian		Editorial
Cholinesterase inhibitors for mild cognitive impairment	Dong, Bi Rong		Authoring
Cholinesterase inhibitors for rarer dementias associated with neurological conditions	Zhang, Zongwang		Authoring
Cholinesterase inhibitors for the treatment of delirium in non-ICU settings	Creavin, Sam T		Authoring
Clinical judgement by primary care physicians for the diagnosis of all-cause dementia or cognitive impairment in symptomatic people	Graff, Maud JL	105	Authoring
Cognitive reframing for carers of people with dementia (105)	Woods, Bob		Authoring
Cognitive stimulation to improve cognitive functioning in people with dementia	Bahar-Fuchs, Alex	118	Authoring
Cognitive training and cognitive rehabilitation for older adults with mild to moderate dementia (118)	Eschen, Anne		Authoring
Cognitive training for older people and people with mild cognitive impairment	Bahar-Fuchs, Alex		Authoring
Cognitive training for people with mild to moderate dementia	Orgeta, Vasiliki		Editorial
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's Disease	Gates, Nicola J		Authoring
	Gates, Nicola J		Authoring
	Gates, Nicola J		Authoring
	Ritchie, Craig	DTA 19	Authoring
	Floravanti, Mario		Authoring
	Karkou, Vicky		Authoring
	Jones, Roy	4	Authoring
	Malouf, Reem	9	Authoring
	Salt, Dallas P		Authoring

How can CRSU help your group

Studies needing updates

Donepezil for vascular dementia

Galantamine for vascular dementia

Rivastigmine for vascular dementia

Non-pharmacological (multi-component)
interventions for managing delirium

IQCODE for detection of dementia

AD-8 for detection for dementia

Exercise interventions in dementia

How can CRSU help your group

Studies needing updates	Can CRSU help
Donepezil for vascular dementia	NMA of cholinesterase inhibitors in vascular dementia
Galantamine for vascular dementia	
Rivastigmine for vascular dementia	
Non-pharmacological (multi-component) interventions for managing delirium	Component NMA of non-pharm interventions
IQCODE for detection of dementia (x3)	Overview of informant tools for detection of dementia Comparative DTA
AD-8 for detection for dementia	
Exercise interventions in dementia	Implications for research – what size should the next study be.....

NIHR CRSU - Complex Reviews Support Unit

About us

The Team

Apply for CRSU Support

Materials and Guidance

Courses and Conferences

FAQs

Contact us >

Contact us

Moira Sim

Project Manager

NIHR Complex Reviews Support Unit (CRSU)

1 Lilybank Gardens

University of Glasgow

Glasgow

G12 8RZ

Telephone: 0141 330 6826

E-mail: moira.sim@glasgow.ac.uk

Website: www.nihrcrsu.org

Twitter: @NIHRCRSU



University
of Glasgow



UNIVERSITY OF
LEICESTER

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



NHS

National Institute for
Health Research